Amycretin vs CagriSema
Last updated: October 27, 2026 · 6 min read · By the Grey Peptides Editorial Board
- Both are Novo Nordisk's attempts to add amylin's fullness signal to GLP-1. CagriSema does it with two molecules injected together, cagrilintide and semaglutide; amycretin does it with one molecule that acts on both receptor types.
- Amycretin's best result, 24.3% weight loss at 36 weeks on its top weekly dose, came from a 125-person early trial. CagriSema's 20.4% at 68 weeks came from a 3,417-person phase 3 trial. The two figures are not comparable.
- CagriSema has been with the FDA since December 2025 7; Drugs@FDA listed no approval when we searched on October 27, 2026 9. Amycretin is earlier: no application had been filed in the US or EU when we checked on September 30, 2026.
Side by side
Amycretin Medium and CagriSema High pursue the same idea: GLP-1 drugs such as semaglutide reduce appetite, and amylin, a hormone released with insulin, adds a separate fullness signal. CagriSema combines two drugs, cagrilintide, an amylin analogue, and semaglutide, each at 2.4 mg, given together once a week 1 2. Amycretin is a single molecule: in laboratory tests it activated human GLP-1, amylin and calcitonin receptors, and in obese rats 21 days of treatment cut food intake by 47% and body weight by 18% 3. The table is read from our encyclopedia entries.
| Field | Amycretin | CagriSema |
|---|---|---|
| Encyclopedia entry | Amycretin Full entry | CagriSema Full entry |
| Molecule class | Peptide | Blend or mixture |
| Category | Pipeline & In-Development | Pipeline & In-Development |
| FDA status | In Clinical Trials | In Development |
| Approved elsewhere | None recorded | None recorded |
| Evidence grade | Medium | High |
| Half-life | Suitable for weekly SC / daily oral | Cagrilintide 159-195 h; semaglutide 145-165 h (given together weekly, phase 1b) |
| Formula | Not stated | Not stated |
| Molecular weight | Not stated | Not stated |
| WADA 2026 | Prohibited (S0 catch-all) | Prohibited (S0 catch-all) |
| WADA 2027 | Prohibited (S0 catch-all) | Prohibited (S0 catch-all) |
| In one line | Novo Nordisk's investigational single-molecule GLP-1 and amylin receptor agonist, tested as a daily tablet and a weekly injection: in a phase 1b/2a trial the 60 mg weekly dose gave a mean weight change of -24.3% at 36 weeks against -1.1% on placebo. Not approved anywhere. | Novo Nordisk's next-generation obesity injection — NDA filed December 2025; not on FDA's list of 2026 novel drug approvals as of October 20, 2026. The first GLP-1 + amylin fixed-dose combination submitted to FDA. |
| Mechanism | A single peptide that activates both the GLP-1 receptor and the amylin receptor, combining the appetite-suppressant and gastric-emptying effects of GLP-1 agonism with the satiety, glucagon-suppression, and gastric-emptying effects of amylin agonism. The unimolecular approach mirrors the success of tirzepatide's GLP-1/GIP dual agonism in a single molecule rather than requiring a fixed-dose combination like CagriSema. | Dual-mechanism appetite suppression and weight loss. Semaglutide activates the GLP-1 receptor, slowing gastric emptying, suppressing glucagon, and acting centrally on hypothalamic appetite circuits. Cagrilintide activates amylin and calcitonin receptors (amylin is co-secreted with insulin from pancreatic beta cells), which independently reduce food intake, enhance satiety, and appear to restore leptin sensitivity. Combining the two mechanisms produces additive-to-synergistic weight loss in clinical trials. |
| Sources in the entry | 9 | 7 |
| Study cards | 6 | 5 |
| Dosage page | None | Dosage page |
Amycretin: early but striking
Amycretin has been tested two ways. As a weekly injection, in a phase 1b/2a trial of 125 adults, doses were escalated to maintenance levels of 1.25 to 60 mg. Weight changed by -24.3% against -1.1% on placebo at 60 mg and by -22.0% against +1.9% at 20 mg after 36 weeks, and by -16.2% at 5 mg after 28 weeks; gastrointestinal events were the most common and mostly mild to moderate 4. As a daily tablet, the first trial in 144 adults tested single doses, ten-day courses and twelve-week escalations up to two 50 mg tablets a day; adverse events affected 62%, all mild or moderate and commoner at higher doses 5. A 2026 review reports weight loss of up to 13.1% on the tablet over 12 weeks 6.
These are small, early trials, with short durations and doses still being explored. They show what the molecule can do, not what a phase 3 trial will find.
CagriSema: phase 3 and a filing
CagriSema's evidence is far larger. In REDEFINE 1, 3,417 adults without diabetes received CagriSema, semaglutide alone, cagrilintide alone or placebo for 68 weeks. Counting everyone randomised, weight fell 20.4% on CagriSema against 3.0% on placebo; gastrointestinal events affected 79.6% against 39.9%, mostly transient and mild to moderate 1. In REDEFINE 2, in 1,206 adults with type 2 diabetes, the loss was 13.7% against 3.4% 2.
Novo Nordisk filed CagriSema with the FDA in December 2025 7. In February 2026 the company reported that it had lost its head-to-head trial against Lilly's tirzepatide 8. Drugs@FDA listed no approval for it when we searched on October 27, 2026 9.
Why the numbers cannot be lined up
It is tempting to read 24.3% against 20.4% as amycretin winning. The comparison does not hold. The amycretin figure comes from one dose arm of a trial of 125 people, over 36 weeks; the CagriSema figure comes from a phase 3 trial of 3,417 people, counting everyone randomised whether or not they kept taking the drug, over 68 weeks 4 1. The early trial also lost many participants, mostly for reasons other than side effects 4. Until amycretin has phase 3 results, its figures show what the molecule did in a small early trial, not that it is better.
One practical difference is already visible: amycretin has been tested as a daily tablet 5, while CagriSema's phase 3 trials gave both components by weekly injection at 2.4 mg each 1 2.
Where each stands (as of October 27, 2026)
Neither is approved anywhere. CagriSema was filed with the FDA in December 2025 7, and Drugs@FDA listed no approval on October 27, 2026 9. Amycretin is investigational; Drugs@FDA held no application and EMA's register had no entry when we checked on September 30, 2026 7, and still no approval on October 27, 2026 9. Since neither is approved, nothing sold online under either name is an approved medicine. Our guide to the amylin drugs places both alongside petrelintide and eloralintide.
How the differences add up
CagriSema is the further along of the two, with two published phase 3 trials and a filing 1 2 7, and also the one reported to have lost a head-to-head trial against tirzepatide 8. Amycretin is a single molecule that has been tested as an injection and as a tablet, with large early results but no phase 3 data yet 4 5. Doses on this page are those studied in trials, not recommendations.
Frequently asked questions
Is amycretin better than CagriSema?
It is too early to say. Amycretin's 24.3% weight loss at 36 weeks came from a 125-person early trial; CagriSema's 20.4% at 68 weeks came from a 3,417-person phase 3 trial counting everyone randomised. No trial has compared them.
What is the difference between amycretin and CagriSema?
CagriSema is two drugs, cagrilintide and semaglutide, injected together; amycretin is one molecule that acts on both GLP-1 and amylin receptors, tested as a weekly injection and as a daily tablet.
When will amycretin be available?
It is investigational: no application was filed at the FDA or EMA when we checked on September 30, 2026, and Drugs@FDA listed no approval on October 27, 2026.
Related on Grey Peptides
Sources
- Garvey, W. T., et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 393(7), 635-647. PMID: 40544433
- Davies, M. J., et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med, 393(7), 648-659. PMID: 40544432
- Kuhre, R. E., et al. (2025). The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine, 118, 105862. PMID: 40706446
- Dahl, K., et al. (2025). Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet, 406(10499), 149-162. PMID: 40550231
- Gasiorek, A., et al. (2025). Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet, 406(10499), 135-148. PMID: 40550229
- Fu, L., et al. (2026). Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives. Metabolism, 179, 156594. PMID: 41850421
- Grey Peptides dataset records for both compounds (status, filing dates and studied doses as sourced on each entry); read October 27, 2026.
- Clinical Trials Arena. Novo Nordisk's CagriSema bested by Lilly's Zepbound in head-to-head trial, February 23, 2026; read October 27, 2026.
- US FDA, Drugs@FDA (openFDA drugsfda endpoint), searched October 27, 2026 for cagrilintide and amycretin as active ingredients: no approved application.
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead